SPOTLIGHT: Targeted Genetics study on hold


Seattle-based Targeted Genetics has decided to put its lead drug trial on hold after one of the patients in the study became seriously ill. Researchers have stopped dosing volunteers in the early-stage trial for an experimental therapy for inflammatory arthritis--known as tgAAC94--and patients in the study are being monitored. Analysts noted that it's too early to tell if this is a temporary or permanent setback for Targeted Genetics. Release